大型无蒂结直肠病变分块EMR后12个月首次监测结肠镜检查的安全性
本研究回顾性分析前瞻性收集的数据库,纳入2019年8月至2023年4月本中心因≥20 mm无蒂结直肠病变行分块EMR并接受首次监测的患者,比较6个月与12个月监测组的复发率。结果显示6个月和12个月监测的总体复发率均为10.0%,12个月监测对选择性病变似乎可接受。
要点
- 分块EMR后12个月首次监测的总体复发率为10.0%(10/100)。
- 6个月监测组复发率为10.0%(46/461),两组复发率相同。
- 12个月监测组病变更小、更多为锯齿状病变、更多采用冷分块EMR。
核心结论
- 对于选择性≥20 mm无蒂结直肠病变,分块EMR后12个月监测似乎可接受。
- 作者认为需要对选择性病变开展比较6个月与12个月首次监测的随机试验。
研究设计与样本
- 本研究回顾性分析一个前瞻性收集的数据库,纳入2019年8月至2023年4月本中心所有转诊行内镜下切除的结直肠病变。
- 共561个≥20 mm无蒂病变接受首次随访,其中443例患者的490个病变分配至6个月监测,65例患者的的71个病变分配至12个月监测。
- 分配至6个月监测但直至10个月后才返回的24例患者的29个病变,其复发数据纳入12个月监测组。
主要发现
- 12个月监测组病变较6个月监测组更小(平均大小25.9 ± 6.1 mm vs 37.0 ± 17.4 mm)。
- 12个月监测组较6个月监测组更多为锯齿状病变(63.4% vs 9.6%),更多采用冷分块EMR(74.6% vs 20.4%)。
- 6个月和12个月监测的总体复发率分别为10.0%(46/461)和10.0%(10/100)。
- 6个月和12个月监测的平均复发大小分别为10.9 ± 6.2 mm和5.0 ± 3.1 mm。
- 6个月监测组中1例患者在分块EMR部位发生癌,6个月或12个月监测的其他复发均无癌或高级别异型增生。
关键数值与推荐
- 指南推荐≥20 mm无蒂结直肠病变分块EMR后首次内镜监测在6个月进行。
- 12个月监测组病变平均大小25.9 ± 6.1 mm,6个月监测组为37.0 ± 17.4 mm。
- 6个月监测组复发率10.0%(46/461),12个月监测组10.0%(10/100)。
临床怎么用
- 对于选择性≥20 mm无蒂结直肠病变,分块EMR后12个月首次监测似乎可接受。
- 作者认为需要对选择性病变开展随机试验比较6个月与12个月首次监测。
局限性
- 本研究为回顾性分析。
- 本研究数据来自本中心,原文未报告多中心数据。
- 12个月监测组样本量较小(65例患者的71个病变)。
- 作者认为需要对选择性病变开展随机试验比较6个月与12个月首次监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: After piecemeal EMR (pEMR) of nonpedunculated colorectal lesions ≥20 mm, guidelines recommend first endoscopic surveillance at 6 months. However, initial surveillance at 12 months may be adequate for selected low-risk lesions and could save the cost, risk, and inconvenience of 1 surveillance examination. METHODS: This study retrospectively examined a prospectively collected database of all colorectal lesions referred to our center for endoscopic resection between August 2019 and April 2023. We report recurrence rates of patients with colorectal lesions ≥20 mm removed by pEMR who were assigned to 6-month first surveillance or to 12-month first surveillance (or assigned to a 6-month surveillance visit but did not return until after 10 months). RESULTS: There were 561 nonpedunculated lesions ≥20 mm that underwent first follow-up, including 490 lesions in 443 patients assigned to 6-month surveillance and 71 lesions in 65 patients assigned to 12-month surveillance. Lesions assigned to 12-month surveillance were smaller (mean size, 25.9 ± 6.1 mm vs 37.0 ± 17.4 mm), more likely serrated (63.4% vs 9.6%), and more often removed by cold pEMR (74.6% vs 20.4%). Twenty-nine lesions in 24 patients assigned to 6-month surveillance presented after 10 months, and their recurrence data were included in the group assigned to 12-month surveillance. Overall recurrence rates at 6 months and 12 months were 10.0% (46 of 461) and 10.0% (10 of 100), respectively. Mean recurrence sizes at 6 and 12 months were 10.9 ± 6.2 mm and 5.0 ± 3.1 mm, respectively. One patient in the 6-month surveillance group had cancer at the pEMR site, but no other recurrences at 6 or 12 months had either cancer or high-grade dysplasia. CONCLUSIONS: Twelve-month surveillance seems acceptable for selected colorectal lesions ≥20 mm removed by pEMR. A randomized trial comparing initial 6-month versus 12-month surveillance is warranted for selected lesions.
引用
- Bobay MC, Lahr RE, Shultz J, et al. Safety of first surveillance colonoscopy at 12 months after piecemeal EMR of large nonpedunculated colorectal lesions. Gastrointest Endosc. 2024. PMID: 38750975. doi:10.1016/j.gie.2024.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。